Anti-tumor activity of splice-switching oligonucleotides

Nucleic Acids Research

Volumn 38, Issue 22, 2010, Pages 8348-8356

  Bauman, John A ^a   Li, Shyh Dar ^a   Yang, Angela ^a   Huang, Leaf ^a   Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA PRECURSOR; OLIGONUCLEOTIDE; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN BCL XS; SOLID LIPID NANOPARTICLE; SPLICE SWITCHING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL MOUSE; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; GENE SWITCHING; GENETIC TRANSFECTION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA HYBRIDIZATION; RNA SEQUENCE; TOXICITY TESTING; TUMOR XENOGRAFT; UPREGULATION;

ALTERNATIVE SPLICING; ANIMALS; BCL-X PROTEIN; CELL LINE, TUMOR; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; OLIGONUCLEOTIDES; RNA PRECURSORS; RNA, MESSENGER;

ANIMALIA;

EID: 78650440393     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq731     Document Type: Article

References (43)

1. Wang, E.T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S.F., Schroth, G.P. and Burge, C.B. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature, 456, 470-476.
2. Lopez-Bigas, N., Audit, B., Ouzounis, C., Parra, G. and Guigo, R. (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett., 579, 1900-1903.
3. Cooper, T.A., Wan, L. and Dreyfuss, G. (2009) RNA and disease. Cell, 136, 777-793.
4. Dominski, Z. and Kole, R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl Acad. Sci. USA, 90, 8673-8677.
5. Sierakowska, H., Sambade, M.J., Agrawal, S. and Kole, R. (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl Acad. Sci. USA, 93, 12840-12844.
6. 0-O-methoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug. Dev., 13, 119-128.
7. Sazani, P., Kang, S.H., Maier, M.A., Wei, C., Dillman, J., Summerton, J., Manoharan, M. and Kole, R. (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res., 29, 3965-3974.
8. Juliano, R.L., Bauman, J., Kang, H. and Ming, X. (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm., 6, 686-695.
9. Graziewicz, M.A., Tarrant, T.K., Buckley, B., Roberts, J., Fulton, L., Hansen, H., Orum, H., Kole, R. and Sazani, P. (2008) An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol. Ther., 16, 1316-1322.
10. Sazani, P., Gemignani, F., Kang, S.H., Maier, M.A., Manoharan, M., Persmark, M., Bortner, D. and Kole, R. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol., 20, 1228-1233.
11. Jearawiriyapaisarn, N., Moulton, H.M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P.L. and Kole, R. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther., 16, 1624-1629.
12. Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J., Li, J., Li, J., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K. et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA, 105, 14814-14819.
13. Svasti, S., Suwanmanee, T., Fucharoen, S., Moulton, H.M., Nelson, M.H., Maeda, N., Smithies, O. and Kole, R. (2009) RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc. Natl Acad. Sci. USA, 106, 1205-1210.
14. Rimessi, P., Sabatelli, P., Fabris, M., Braghetta, P., Bassi, E., Spitali, P., Vattemi, G., Tomelleri, G., Mari, L., Perrone, D. et al. (2009) Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol. Ther., 17, 820-827.
15. Bauman, J., Jearawiriyapaisarn, N. and Kole, R. (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides, 19, 1-14.
16. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., Van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357, 2677-2686.
17. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8, 918-928.
18. Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nunez, G. and Thompson, C.B. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608.
19. Amundson, S.A., Myers, T.G., Scudiero, D., Kitada, S., Reed, J.C. and Fornace, A.J. Jr (2000) An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res., 60, 6101-6110.
20. Lindenboim, L., Borner, C. and Stein, R. (2001) Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains. Cell Death Differ., 8, 933-942.
21. Minn, A.J., Boise, L.H. and Thompson, C.B. (1996) Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J. Biol. Chem., 271, 6306-6312.
22. Mercatante, D.R., Bortner, C.D., Cidlowski, J.A. and Kole, R. (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J. Biol. Chem., 276, 16411-16417.
23. Mercatante, D.R., Mohler, J.L. and Kole, R. (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem., 277, 49374-49382.
24. Taylor, J.K., Zhang, Q.Q., Wyatt, J.R. and Dean, N.M. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol., 17, 1097-1100.
25. Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F. and Hersey, P. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol., 20, 416-426.
26. Leiter, U., Schmid, R.M., Kaskel, P., Peter, R.U. and Krahn, G. (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res., 292, 225-232.
27. Li, S.D. and Huang, L. (2006) Surface-modified LPD nanoparticles for tumor targeting. Ann. NY Acad. Sci., 1082, 1-8.
28. Li, S.D. and Huang, L. (2006) Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm., 3, 579-588.
29. Li, S.D., Chen, Y.C., Hackett, M.J. and Huang, L. (2008) Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther., 16, 163-169.
30. Li, S.D., Chono, S. and Huang, L. (2008) Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther., 16, 942-946.
31. Li, S.D., Chono, S. and Huang, L. (2008) Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control Release, 126, 77-84.
32. John, C.S., Bowen, W.D., Varma, V.M., McAfee, J.G. and Moody, T.W. (1995) Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci., 56, 2385-2392.
33. Vilner, B.J., John, C.S. and Bowen, W.D. (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res., 55, 408-413.
34. Banerjee, R., Tyagi, P., Li, S. and Huang, L. (2004) Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer, 112, 693-700.
35. Zhang, N., Peairs, J.J., Yang, P., Tyrrell, J., Roberts, J., Kole, R. and Jaffe, G.J. (2007) The importance of Bcl-xL in the survival of human RPE cells. Invest. Ophthalmol. Vis. Sci., 48, 3846-3853. (Pubitemid 351261126)
36. Pham, T.Q., Berghofer, P., Liu, X., Greguric, I., Dikic, B., Ballantyne, P., Mattner, F., Nguyen, V., Loc'h, C. and Katsifis, A. (2007) Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. J. Nucl. Med., 48, 1348-1356.
37. Li, S.D. and Huang, L. (2009) Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta, 1788, 2259-2266.
38. Chono, S., Li, S.D., Conwell, C.C. and Huang, L. (2008) An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control Release, 131, 64-69.
39. Li, S.D. and Huang, L. (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm., 5, 496-504.
40. Wan, J., Sazani, P. and Kole, R. (2009) Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int. J. Cancer, 124, 772-777.
41. Bennett, C.F. (2008) In Crooke, S.T. (ed.), Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. CRC Press, Boca Raton, FL, pp. 273-304.
42. Chonghaile, T.N. and Letai, A. (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene, 27(Suppl 1), S149-S157.
43. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J. et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-681.